Standard Bio (Norway)

Sharing data practices is a primary goal for standards development organizations that are signatories of the United Nations Economic Commission for Europe's (UNECE) Declaration for Gender-Responsive Standards and Standards Development. This article presents a data-driven approach to selecting an existing voluntary consensus standard to evaluate for gender responsiveness, and leverages public data to identify potential opportunities for improving its safety impact. The authors found that UL 8400, the Standard for Safety for Virtual Reality, Augmented Reality, and Mixed Reality Technology Equipment was a suitable candidate for the initiative, and they highlight potential safety issues through an analysis of incident data and primary research articles.

In single-cell spatial phenotyping biology, imaging mass cytometry (IMC) stands out as a cutting-edge, highly multiplexed technology driving discoveries across various disease areas. Invitro profiling relies on tumor-derived cancer cell lines, known for their diverse morphologies and phenotypes. A comprehensive analysis of those cell lines presents a direct challenge in predicting cancer progression and drug treatment responses. We demonstrate in our study an adaptable computational workflow we have named IMC Cell Line Profiler as a suite of versatile open-source tools for visual rendering and quantitative segmentation-based analysis of tumor-derived cell lines profiled by IMC. By leveraging our workflow with IMC resolution and multiplexing capabilities, we scrutinized the morphology, phenotypic traits, and spatial arrangement of 10 cultured cell lines from diverse tissues using custom panels of 20-30 metal-labeled antibodies. This allowed us to generate intricate high-dimensional datasets elucidating diverse cellular states with multiple markers. This computational approach was applied to a cisplatin exposure treatment in a resistant cell line to track morpho-phenotypic changes. Our IMC computational study presents new perspectives and applications to profile cell lines as new types of samples and expand the potential of IMC to new fields of discovery.

ObjectiveThis study aimed to evaluate the feasibility, safety, and oncologic outcomes of irreversible electroporation (IRE) using a clustered electrode in patients with locally advanced pancreatic cancer (LAPC).Materials and MethodsIn this single-center prospective cohort study, 13 patients with LAPC (median age, 60 years; range, 48–78 years) underwent clustered electrode IRE between September 2022 and September 2024. Patient characteristics, procedural details, and clinical outcomes were recorded. Endpoints included technical success, procedure-related complications, overall survival (OS), and progression-free survival (PFS).ResultsTumors were located in the pancreatic head in four patients (30.8%) and in the body/tail in nine (69.2%). The median tumor size was 2.4 cm (1.5–4.0 cm), and vascular invasion was present in all patients. Technical success was achieved in all patients. Intraoperative IRE was performed in 11 (84.6%) patients, and 2 (15.4%) patients underwent percutaneous IRE. Gastrointestinal bleeding events as major complications occurred in two patients (15.4%) and, both were successfully controlled by embolization. No 60-day mortality was observed. At a median follow-up of 24.5 months (range, 9.9–33.4 months) after IRE, median OS and PFS from IRE were 20.1 and 14.5 months, respectively.ConclusionIRE using clustered electrodes for LAPC appears to be a feasible therapeutic approach, offering reliable technical success and acceptable safety. Survival outcomes are encouraging; however, larger, controlled studies are required.

This pilot crossover study explored whether the 2–3-hour postprandial glycemic slope may serve as an objective correlate of subjective hunger and psychological eating comfort in cancer patients, addressing the current gap in psycho-oncology where appetite-related distress is assessed almost exclusively through self-report. Seven cancer survivors completed two standardized test days with different preloads used solely to elicit distinct glucose trajectories, allowing examination of the physiological–psychological relationship. Subjective appetite was assessed using VAS ratings while blood glucose was measured over 4 hours. Although satiety did not differ significantly, the preload that attenuated the late postprandial glycemic decline produced a 23% reduction in hunger AUC (p = 0.030) and a significantly higher 2–3 h glucose AUC (p = 0.049), indicating a delayed glycemic dip. The correspondence between a flatter glycemic slope and reduced hunger suggests that postprandial glucose patterns may represent a measurable physiological marker reflecting subjective appetite experience and psychological comfort around eating in cancer populations. These findings introduce the glycemic slope as a potential biomarker that could complement subjective assessments, support psycho-oncological interventions, and improve understanding of appetite-related distress, warranting larger studies integrating validated psychological measures.

The SEG has recently published a clarification note for the SEG-Y_r2.1 format, together with an example file that contains metadata in extended textual headers. This work has been completed in collaboration with the IOGP Geomatics Committee to support organisations that wish to leverage the SEG-Y_r2.1 format and enable the realisation of wider industry objectives around transformational workflows through the adoption and application of open standards. This will serve to enable the automated exchange of seismic data and reduce the risk of introducing positional error through deficiencies in current data transfer and loading processes. The inclusion of extended textual headers in the SEG-Y format presents an opportunity to increase both efficiency and reliability and address the risks and limitations in seismic data management processes that have barely changed for decades. IOGP P format records are presented as an already established solution to addressing the issue of missing or unstructured positioning metadata.

Abstract Description Patients with immune mediated inflammatory diseases (IMIDs) have an increased risk for cardiovascular (CV) disease and metabolic disorders, which are often underpredicted by traditional risk calculators. These analyses aimed to determine whether previously validated proteomic surrogates of CV event risk, kidney health risk, dementia risk, and other key cardiometabolic (CM) measures can provide a better understanding of CM risks associated with IMIDs. SomaSignal® tests (derived from ∼5000 plasma protein measurements using the SomaScan® assay) were applied to a subset (n = 1,743) of samples from the IMID-Biobank at VHIR, including healthy control participants (n = 254) and patients with ulcerative colitis (UC; n = 280), Crohn’s disease (CD; n = 294), rheumatoid arthritis (RA; n = 304), psoriatic arthritis (PsA; n = 304), and plaque psoriasis (PS; n = 307). An exploratory analysis using ANOVA between patients with an IMID, and healthy controls was conducted using a raw p-value cutoff of < 0.05. CV and dementia risk were significantly elevated in UC, CD, RA, and PS compared to healthy controls and risk correlated with disease severity in most cases. Kidney health risk was significantly worse in UC, CD, and RA compared to healthy controls. Multiple CM measures including VO2max, glucose tolerance and visceral fat significantly worsened in IMID patients compared to healthy controls. Together these results suggest SomaSignal® tests may provide a useful tool for assessing CM risk in IMID patients. Topic Categories Translational and Interventional Immunology (TI)

Abstract Description Deciphering the spatial biology of the tumor microenvironment (TME) can inform researchers about the likelihood of therapeutic success. Of particular interest is the spatial organization of immune cells, especially T cells, which can undergo exhaustion resulting in reduced effector functions due to expression of inhibitory markers such as PD-1. Imaging Mass Cytometry™ (IMC™) technology is a quantitative multiplexed spatial imaging technique for assessment of 40-plus biomarkers simultaneously on the same tissue slide without signal amplification or autofluorescence interference. We used IMC technology to investigate the spatial distribution and phenotypic characteristics of immune cells, focusing on exhausted T cells in the TME of multiple cancers. Various IMC imaging modes revealed striking heterogeneity of the TME, including clusters of lymphocytes at the tumor margins, indicative of immune surveillance. Pixel-clustering and single-cell analyses delineated distinct tumor areas based on extent of T cell exhaustion, immune cell density, cell proliferation and stromal components. These findings illustrate the power of IMC technology to elucidate the complex spatial landscape of the TME, which may aid in developing prognostic assessments and guide personalized therapeutic strategies for cancer treatments. For Research Use Only. Not for use in diagnostic procedures. Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)

Abstract Description Mouse models are pivotal for translational research, enabling the detection of therapeutic-induced immune modifications within the tumor microenvironment (TME). We utilized a 40-marker panel targeting tumor and immune markers to investigate the spatial protein composition of the whole mouse embryo, mouse brain and mouse glioblastoma (GBM) tumor sections. Imaging Mass Cytometry™ (IMC™) technology was employed to capture the expression of 40 markers simultaneously while preserving tissue integrity and enabling a flexible workflow without autofluorescence artifacts. Data analysis revealed distinct spatial patterns of tumor and immune markers across the GBM, identifying key features such as necrotic cores, regions of high immune infiltration, proliferating tumor cells and diverse populations of infiltrating immune cells. The wide detection range of expression provided by IMC technology enabled visualization and analysis of clusters exhibiting varying levels of key GBM markers, suggesting a probable dual origin of the GBM, coexistence of pro- and anti-tumorigenic immune responses and overall extreme heterogeneity that can only be visualized with high-plex antibody panels. This approach demonstrates the capability of IMC technology to reveal the complex cellular and structural spatial landscape of the TME in GBM, providing valuable insights into tumor biology and potential therapeutic targets for patient stratification. For Research Use Only. Not for use in diagnostic procedures. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)